These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25075867)

  • 1. Prognostic value of a quantitative analysis of lipoarabinomannan in urine from patients with HIV-associated tuberculosis.
    Kerkhoff AD; Wood R; Vogt M; Lawn SD
    PLoS One; 2014; 9(7):e103285. PubMed ID: 25075867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis.
    Lawn SD; Kerkhoff AD; Vogt M; Wood R
    AIDS; 2012 Aug; 26(13):1635-43. PubMed ID: 22555166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study.
    Lawn SD; Kerkhoff AD; Vogt M; Wood R
    Lancet Infect Dis; 2012 Mar; 12(3):201-9. PubMed ID: 22015305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of the urine lipoarabinomannan assay in HIV-positive, ambulatory patients with CD4 below 200 cells/μl in 2 low-resource settings: A prospective observational study.
    Huerga H; Mathabire Rucker SC; Cossa L; Bastard M; Amoros I; Manhiça I; Mbendera K; Telnov A; Szumilin E; Sanchez-Padilla E; Molfino L
    PLoS Med; 2019 Apr; 16(4):e1002792. PubMed ID: 31039161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults.
    Shah M; Hanrahan C; Wang ZY; Dendukuri N; Lawn SD; Denkinger CM; Steingart KR
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD011420. PubMed ID: 27163343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort.
    Lawn SD; Kerkhoff AD; Burton R; Schutz C; Boulle A; Vogt M; Gupta-Wright A; Nicol MP; Meintjes G
    BMC Med; 2017 Mar; 15(1):67. PubMed ID: 28320384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing.
    Peter J; Theron G; Chanda D; Clowes P; Rachow A; Lesosky M; Hoelscher M; Mwaba P; Pym A; Dheda K;
    BMC Infect Dis; 2015 Jul; 15():262. PubMed ID: 26156025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determine TB-LAM point-of-care tuberculosis assay predicts poor outcomes in outpatients during their first year of antiretroviral therapy in South Africa.
    Kerkhoff AD; Longley N; Kelly N; Cross A; Vogt M; Wood R; Hermans S; Lawn SD; Harrison TS
    BMC Infect Dis; 2020 Jul; 20(1):555. PubMed ID: 32736601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.
    Gupta-Wright A; Peters JA; Flach C; Lawn SD
    BMC Med; 2016 Mar; 14():53. PubMed ID: 27007773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for MTB Culture-Positivity among HIV-Infected Smear-Negative Presumptive Tuberculosis Patients in Uganda: Application of New Tuberculosis Diagnostic Technology.
    Nakiyingi L; Nonyane BA; Ssengooba W; Kirenga BJ; Nakanjako D; Lubega G; Byakika-Kibwika P; Joloba ML; Ellner JJ; Dorman SE; Mayanja-Kizza H; Manabe YC
    PLoS One; 2015; 10(7):e0133756. PubMed ID: 26222142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.
    Dheda K; Davids V; Lenders L; Roberts T; Meldau R; Ling D; Brunet L; van Zyl Smit R; Peter J; Green C; Badri M; Sechi L; Sharma S; Hoelscher M; Dawson R; Whitelaw A; Blackburn J; Pai M; Zumla A
    PLoS One; 2010 Mar; 5(3):e9848. PubMed ID: 20352098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study.
    Gupta-Wright A; Corbett EL; Wilson D; van Oosterhout JJ; Dheda K; Huerga H; Peter J; Bonnet M; Alufandika-Moyo M; Grint D; Lawn SD; Fielding K
    PLoS Med; 2019 Apr; 16(4):e1002776. PubMed ID: 30951533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa.
    d'Elia A; Evans D; McNamara L; Berhanu R; Sanne I; Lönnermark E
    Pan Afr Med J; 2015; 22():4. PubMed ID: 26600904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays.
    Lawn SD; Kerkhoff AD; Vogt M; Wood R
    BMC Med; 2013 Oct; 11():231. PubMed ID: 24168211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.
    Kawasaki M; Echiverri C; Raymond L; Cadena E; Reside E; Gler MT; Oda T; Ito R; Higashiyama R; Katsuragi K; Liu Y
    PLoS Med; 2019 Apr; 16(4):e1002780. PubMed ID: 30978194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the use of adjunct urine lipopolysaccharide lipoarabinomannan in HIV-infected hospitalized patients reduce the utilization of healthcare resources? A post hoc analysis of the LAM multi-country randomized controlled trial.
    Naidoo P; Esmail A; Peter JG; Davids M; Fadul M; Dheda K
    Int J Infect Dis; 2019 Feb; 79():37-43. PubMed ID: 30292891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of Tuberculosis Molecular Bacterial Load Assay Compared to Alere TB-LAM in Urine of Pulmonary Tuberculosis Patients with HIV Co-Infections.
    Mapamba DA; Sauli E; Lalashowi J; Buza J; John J; Mwaisango Z; Tarmo P; Sabi I; Rachow A; Ntinginya NE; Mtafya B
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.
    Thit SS; Aung NM; Htet ZW; Boyd MA; Saw HA; Anstey NM; Kyi TT; Cooper DA; Kyi MM; Hanson J
    BMC Med; 2017 Aug; 15(1):145. PubMed ID: 28774293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis Case Finding With Combined Rapid Point-of-Care Assays (Xpert MTB/RIF and Determine TB LAM) in HIV-Positive Individuals Starting Antiretroviral Therapy in Mozambique.
    Floridia M; Ciccacci F; Andreotti M; Hassane A; Sidumo Z; Magid NA; Sotomane H; David M; Mutemba E; Cebola J; Mugunhe RJ; Riccardi F; Marazzi MC; Giuliano M; Palombi L; Mancinelli S
    Clin Infect Dis; 2017 Nov; 65(11):1878-1883. PubMed ID: 29020319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease.
    Lawn SD; Edwards DJ; Kranzer K; Vogt M; Bekker LG; Wood R
    AIDS; 2009 Sep; 23(14):1875-80. PubMed ID: 20108382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.